Literature DB >> 20610883

Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.

Takashi Ito1, Motohiro Kato, Koji Chiba, Osamu Okazaki, Yuichi Sugiyama.   

Abstract

Cytochrome P450 2D6 (CYP2D6) is an enzyme with a large interindividual variability in its metabolic activity due to genetic polymorphisms. In the present study, both its intrinsic metabolic activity (CL(int,CYP2D6,app)) relative to extensive metabolizers (EM) and its variability were estimated by analyzing the urinary metabolic ratios (MR) based on the well-stirred model. Sparteine and debrisoquine were considered to be appropriate probes for our methodology, whereas dextromethorphan was not appropriate since the formation of its metabolite of interest is not described by the well-stirred model. From the analysis of MRs of sparteine and debrisoquine for Caucasian subjects in the literature, CL(int,CYP2D6,app) for intermediate metabolizers (IM) was estimated to be approximately 15% of that for EM. The coefficient of variability (CV) of CL(int,CYP2D6,app) was estimated to be approximately 60% for both EM and IM and 100% for the combined population of ultrarapid metabolizer, EM and IM [i.e., the non-poor metabolizer (non-PM) population]. Simulation of exposure in the non-PM population showed that the CV of exposure was 140% for dextromethorphan and 71% for metoprolol, which reflected the reported values of 110% and 53% for dextromethorphan and metoprolol, respectively. The present study should be useful for predicting the interindividual variability in exposure to investigational drugs that are metabolized by CYP2D6.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610883     DOI: 10.2133/dmpk.25.243

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  5 in total

1.  Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Authors:  Waheed Adeola Adedeji; Sharon Iyobor Igbinoba; Titilayo O Fakeye; Ibrahim Adebayo Oladosu; Fatai Adewale Fehintola; Qing Ma; Gene D Morse
Journal:  Expert Rev Clin Pharmacol       Date:  2017-08-30       Impact factor: 5.045

2.  Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.

Authors:  Huybrecht T'jollyn; Jan Snoeys; Jan Van Bocxlaer; Lies De Bock; Pieter Annaert; Achiel Van Peer; Karel Allegaert; Geert Mannens; An Vermeulen; Koen Boussery
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

3.  The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva.

Authors:  Ye Jin; Shuquan Zhang; Pei Hu; Xin Zheng; Xiaoduo Guan; Rui Chen; Shuyang Zhang
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

4.  CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D610 on Interindividual Variation in a Chinese Population.

Authors:  Rui Chen; Xin Zheng; Pei Hu
Journal:  Front Pharmacol       Date:  2017-05-02       Impact factor: 5.810

5.  Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.

Authors:  J Kevin Baird; Melva Louisa; Rintis Noviyanti; Lenny Ekawati; Iqbal Elyazar; Decy Subekti; Krisin Chand; Anggi Gayatri; Saraswati Soebianto; Chelzie Crenna-Darusallam; Dwi Djoko; Bambang Dwi Hasto; Dubel Meriyenes; David Wesche; Erni J Nelwan; Inge Sutanto; Herawati Sudoyo; Rianto Setiabudy
Journal:  JAMA Netw Open       Date:  2018-08-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.